Table V.
Comparison of toxic and side effects between icotinib and pemetrexed in the treatment of lung adenocarcinoma [n (%)].
| Total number of cases | ||||
|---|---|---|---|---|
| Toxic and side effects | Icotinib group (n=69) | Pemetrexed group (n=63) | χ2 | P-value |
| Leukopenia | 8 (11.59) | 30 (47.62)a | 20.850 | <0.001 |
| Neutropenia | 4 (5.80) | 40 (63.49)a | 49.330 | <0.001 |
| Thrombocytopenia | 5 (7.25) | 23 (36.51)a | 16.870 | <0.001 |
| Anemia | 3 (4.35) | 15 (23.81)a | 10.590 | <0.001 |
| Nausea and vomiting | 9 (13.04) | 46 (73.02)a | 48.730 | <0.001 |
| Constipation or diarrhea | 14 (20.29) | 15 (23.81) | 0.238 | 0.626 |
| Rash | 27 (39.13) | 5 (7.94)a | 17.450 | <0.001 |
| Alopecia | 3 (4.35) | 5 (7.94) | 0.278 | 0.619 |
| Fatigue | 7 (10.14) | 35 (55.56)a | 31.300 | <0.001 |
| Peripheral nerve toxicity | 6 (8.70) | 22 (34.92)a | 13.550 | <0.001 |
| Stomatitis | 5 (7.25) | 5 (7.94) | 0.024 | 0.878 |
| Hepatotoxicity | 12 (17.39) | 13 (20.63) | 0.226 | 0.635 |
| Neurotoxicity | 1 (1.45) | 1 (1.59) | 0.420 | 0.517 |
Fisher's test was used when the frequency was T<5.
a
P<0.05, compared to the icotinib group.